Upcoming Events
  1. Australian Lung Cancer Conference 2020

    February 19 - February 21
  2. ALTG Open Scientific Advisory Committee Meeting

    February 19 @ 2:00 pm - 5:00 pm
  3. ALTG Open Management Advisory Committee Meeting

    February 20 @ 7:00 am - 8:00 am
  4. ALTG Strategic Planning Workshop

    February 21 @ 7:00 am - 9:00 am
  5. 6th ALTG Lung Cancer Preceptorship

    October 23 @ 8:00 am - October 24 @ 5:00 pm

Concepts in development

ALTG 15/004 BR.34: A randomized trial of durvalumab (MEDI4736) and tremelimumab ± platinum-based chemotherapy in patients with high-risk advanced or metastatic (stage IIIB/IV) squamous or non-squamous NSCLC – L Seymour (CCTG), B Hughes (ALTG)

  • The overall objective of this trial is to determine if durvalumab + tremelimumab, ± first-line platinum-based combined chemotherapy, improves overall survival in patients with incurable advanced or metastatic NSCLC
  • Planned global recruitment 300
  • Likely to progress in 2017 pending outcome of ongoing discussions between ALTG and CCTG

ALTG 16/002 Fear of recurrence in patients with early stage NSCLC – S McLachlan

  • Protocol in development
  • Project grant submission planned for 2017
  • If successful, anticipated study start late 2018

ALTG 16/003 Optimal duration of treatment with immunotherapy (advanced NSCLC) – K O’Byrne

  • Project grant unsuccessful in 2016; resubmission in preparation

ALTG 16/004 SCRIBE: A phase 2 study of nivolumab with radiotherapy or nivolumab with ipilimumab in the treatment of small cell lung cancer brain metastases – P Mitchell

  • This study examines nivolumab in combination with radiotherapy and the activity of nivolumab in combination with ipilimumab in SCLC brain metastases
  • Planned recruitment 53
  • Initial approval for concept received from Bristol-Myers Squibb
  • Protocol and PIC provided to BMS September 2016

ALTG 16/005 OSCILLATE: Phase 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced NSCLC – B Solomon

  • This study aims to determine the efficacy, safety, and feasibility of alternating osimertinib and gefitinib in patients with EGFR-T790M mutation positive NSCLC
  • Planned recruitment 45 from 15 sites
  • Protocol finalised and funding approved by AstraZeneca
  • Central ethics submission is planned for Q1 2017
  • Anticipated FPI Q3 2017

ALTG 16/007 ALKTERNATE: Single arm phase 2 trial in ALK-rearranged NSCLC alTERNATing lortatinib with crizotinib after progression on first line crizotinib – N Pavlakis

  • This study aims to identify whether a fixed, ongoing alternating schedule of lorlatinib with crizotinib results in ongoing disease control and suppression of detectable innate or acquired ALK gene resistance mutations in blood; and to determine if ALK gene resistance mutations in circulating tumour DNA can be used to identify participants developing resistance before progression is clinically evident
  • Planned recruitment 40 from 15 sites
  • Concept submitted to Pfizer for review Dec 2016

ALTG 16/008 NINA: Phase 2 single arm study of nintedanib in combination with avelumab as second line therapy in patients with advanced NSCLC – N Pavlakis

  • This study aims to assess the activity of nintedanib combined with avelumab after patients have progressed on prior platinum doublet chemotherapy in NSCLC
  • Planned recruitment 64 from 16 sites
  • Concept submitted to Merck for review Dec 2016

ALTG 16/009 A Phase 2 study of durvalumab plus tremelimumab in patients with relapsed EGFR mutant NSCLC – C Lee

  • This study aims to evaluate the efficacy and tolerability of combination durvalumab plus tremelimumab in patients with relapsed EGFR mutant NSCLC
  • Planned recruitment 50 from 20 sites
  • Concept submitted to AstraZeneca for review Dec 2016

ALTG 16/012 STIMULI: A Phase 2 trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy – European Thoracic Oncology Platform (ETOP) study – P Mitchell (ALTG)

  • To evaluate if chemo-radiotherapy and prophylactic cranial irradiation followed by nivolumab and ipilimumab consolidation have better outcome (PFS and OS) compared to patients treated with chemo-radiotherapy and prophylactic cranial irradiation without nivolumab and ipilimumab consolidation
  • Planned global recruitment 260
  • Study has recruited 84 patients to date with recruitment estimated to continue to 2019
  • Preliminary feasibility of ALTG sites circulated Dec 2016
  • Under consideration for ALTG participation

ALTG 17/001 Active surveillance in patients with MPM: a prospective single arm phase II trial – A Nowak

  • Project grant submission in preparation